<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea K Ng, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Classic Hodgkin lymphoma (cHL) includes the following histologic subtypes: nodular sclerosis cHL, lymphocyte-rich cHL, mixed cellularity cHL, and lymphocyte-depleted cHL.</p><p>This topic will discuss pretreatment evaluation, staging, and prognosis of cHL.</p><p>Clinical presentation and diagnosis of cHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a>.)</p><p>Evaluation of nodular lymphocyte-predominant Hodgkin lymphoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H405725343"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Pretreatment evaluation includes history and physical examination, laboratory studies, imaging, and specialized studies to assess the patient's fitness for treatment and to determine the disease stage.</p><p>Evaluation to diagnose cHL is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H2699950361"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>History should include the extent and duration of adenopathy, pruritus, fatigue, abdominal fullness/pain, and B symptoms (ie, fevers, sweats, weight loss). History should also include smoking history and comorbid conditions, including cardiovascular, respiratory, and neuropathic symptoms. Criteria for B symptoms are provided below. (See <a class="local">'B symptoms'</a> below.)</p><p>Performance status should be determined using either the Karnofsky or Eastern Cooperative Oncology Group (ECOG) scales  (<a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">table 1</a>).</p><p>Physical examination should evaluate the size, number, and specific regions of nodal enlargement  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>), presence of splenomegaly or hepatomegaly, and examination of the cardiac and respiratory systems.</p><p class="headingAnchor" id="H2026977998"><span class="h2">Laboratory studies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematology</strong> – Complete blood count (CBC) with differential count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemistry</strong> – Electrolytes, kidney and liver function tests, calcium, albumin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammation</strong> – Erythrocyte sedimentation rate (ESR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis B</strong> – Hepatitis B surface antigen (HBsAg) and antibodies against hepatitis B core antigen (anti-HBc). For the patient who is HBsAg positive, further testing should include HBeAg, anti-HBe, and HBV DNA level. (See  <a class="medical medical_review" href="/z/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults", section on 'Serologic markers'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis C</strong> – Serologic testing for hepatitis C should include both antibody testing and hepatitis C RNA assays. (See  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Diagnostic techniques'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HIV</strong> – Human immunodeficiency virus (HIV) serology. (See  <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">"Initial evaluation of adults with HIV", section on 'HIV-related testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy test</strong> for females of childbearing age.</p><p></p><p class="headingAnchor" id="H3660554050"><span class="h2">Cardiac function</span><span class="headingEndMark"> — </span>Left ventricular ejection fraction (LVEF) should be evaluated by echocardiogram or radionuclide ventriculogram. LVEF should generally be ≥50 percent if doxorubicin-based chemotherapy is a consideration. (See  <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p class="headingAnchor" id="H437873647"><span class="h2">Pulmonary function tests</span><span class="headingEndMark"> — </span>Pulmonary function tests (PFTs), including diffusing capacity (DLCO) should be performed if chemotherapy that includes <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> (eg, ABVD, BEACOPP) is a consideration. In general, DLCO ≥60 percent is acceptable for treatment with bleomycin.</p><p class="headingAnchor" id="H4146606629"><span class="h2">PET/CT</span><span class="headingEndMark"> — </span>Positron emission tomography/computed tomography (PET/CT) is the mainstay of imaging for staging cHL. PET is highly sensitive for the presence of cHL, but PET cannot be used to evaluate the brain (because of its avidity for fluorodeoxyglucose [FDG]) and because sites of infection or inflammation may also be PET positive. In some cases, diagnostic CT may clarify ambiguous PET findings or better define the relevant anatomy, as discussed below. (See <a class="local">'Diagnostic CT'</a> below and <a class="local">'Magnetic resonance imaging'</a> below.)</p><p>PET/CT should extend from skull base to mid-thigh, and results should be reported using the Deauville score  (<a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">table 2</a>), which uses FDG uptake in the mediastinal blood pool and liver as internal controls. Liver involvement may be suggested by focal FDG uptake (with or without disseminated nodules). Some experts suggest that PET/CT findings suspicious for liver involvement should be confirmed by ultrasound, intravenous contrast-enhanced CT, or MRI [<a href="#rid1">1</a>].</p><p>The high sensitivity and specificity of PET/CT for staging of cHL was confirmed in a meta-analysis of 20 studies [<a href="#rid2">2</a>]. If PET is unavailable, intravenous contrast-enhanced CT of chest, abdomen, and pelvis is an acceptable alternative for staging. (See <a class="local">'Diagnostic CT'</a> below.)</p><p>FDG-positive findings at locations that are inconsistent with a clinical presentation of cHL may require additional imaging, specialized studies, and/or pathologic confirmation. However, it should be recognized that unusual sites or patterns of involvement may be found in HIV-infected patients or other immunosuppressed individuals. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Less common presentations'</a>.)</p><p class="headingAnchor" id="H4160547242"><span class="h2">Other imaging</span></p><p class="headingAnchor" id="H4104741119"><span class="h3">Diagnostic CT</span><span class="headingEndMark"> — </span>Diagnostic CT of the neck with intravenous contrast should be performed if PET is positive in the neck or if radiation therapy to the neck is a consideration. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p>Some experts suggest a diagnostic quality CT (with or without intravenous contrast) of the chest, abdomen, and/or pelvis that includes all areas identified as abnormal on PET/CT. In some settings, a low-dose CT is performed at the time of PET (primarily for attenuation correction of PET images), and this may not adequately characterize the anatomy. A diagnostic quality CT (ie, higher photon strength) can better characterize ambiguous PET findings and/or determine the size of a mediastinal or other large tumor mass. (See <a class="local">'Bulky disease'</a> below.)</p><p class="headingAnchor" id="H2350451364"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>MRI can be used for anatomical imaging of PET-positive lesions to characterize involvement of certain organs (eg, brain, liver). (See <a class="local">'PET/CT'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS)</strong> – For patients with neurologic findings that are consistent with CNS involvement by cHL, the CNS should be evaluated by MRI (with and without gadolinium). Patients with neurologic findings should also undergo lumbar puncture with cytology. As described above, PET is not useful for evaluation of the CNS. (See <a class="local">'PET/CT'</a> above.)</p><p></p><p class="bulletIndent1">CNS involvement with cHL is rare. However, various paraneoplastic syndromes (eg, cerebellar degeneration, chorea, neuromyotonia, limbic encephalitis, subacute sensory neuropathy, subacute lower motor neuropathy, stiff person syndrome) have been described in association with cHL. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Less common presentations'</a> and  <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p></p><p class="bulletIndent1">If the patient is not a candidate for MRI, diagnostic CT with intravenous contrast is an acceptable alternative. (See <a class="local">'Diagnostic CT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other sites</strong> – MRI is valuable for imaging the neck, liver, or other PET-positive sites where further anatomic definition is needed for staging or treatment planning.</p><p></p><p class="bulletIndent1">Diagnostic quality CT, with or without intravenous contrast, is an acceptable alternative to MRI in such settings. (See <a class="local">'Diagnostic CT'</a> above.)</p><p></p><p class="headingAnchor" id="H1700966046"><span class="h3">Chest radiography</span><span class="headingEndMark"> — </span>A chest radiograph may be useful if a mediastinal mass is detected, but chest CT is generally used to determine if the mass constitutes "bulky" disease, as described below. (See <a class="local">'Bulky disease'</a> below.)</p><p class="headingAnchor" id="H1373107048"><span class="h2">Other procedures</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow evaluation</strong> – Bone marrow aspirate and biopsy is generally <strong>not</strong> required, because it has little or no therapeutic consequences [<a href="#rid3">3,4</a>].</p><p></p><p class="bulletIndent1">We suggest bone marrow examination only when unexplained cytopenias are present in the setting of a PET that is negative for bone marrow involvement. A homogeneous pattern of uptake in the marrow should not be assumed to be marrow involvement, but skeletal PET/CT lesions at ≥3 sites should be interpreted as bone marrow involvement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture</strong> – For patients with neurologic symptoms or signs, the CNS should be evaluated by lumbar puncture with cytology and by MRI, as described above. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Staging of cHL is essential for treatment stratification, as described below. (See <a class="local">'Treatment stratification'</a> below.)</p><p class="headingAnchor" id="H1434167946"><span class="h2">Staging notation</span><span class="headingEndMark"> — </span>Staging of cHL is based on the Lugano classification [<a href="#rid1">1</a>], which was derived from the Ann Arbor staging system with Cotswolds modifications [<a href="#rid5">5,6</a>]. </p><p>Staging notation captures the extent of nodal involvement and other disease features (eg, B symptoms, bulky disease, and/or extranodal involvement):</p><p class="bulletIndent1"><span class="glyph">●</span>A numerical stage (I to IV) based on the sites of involvement  (<a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">table 3</a>). (See <a class="local">'Nodal regions'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I</strong> – Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (I<sub>E</sub>) without nodal involvement. A single lymph node region can include one node or a group of adjacent nodes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage II</strong> – Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (II<sub>E</sub>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage III</strong> – Involvement of lymph node regions or lymphoid structures on both sides of the diaphragm.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage IV</strong> – Additional noncontiguous extralymphatic involvement, with or without associated lymphatic involvement.</p><p></p><p>For the purpose of treatment stratification, stages I and II are considered <strong>early stage</strong> (or limited stage) disease and stages III and IV are considered <strong>advanced stage </strong>disease, as described below. Whether stage II with bulky disease is treated as limited or advanced disease may be determined by certain prognostic factors. (See <a class="local">'Early versus advanced disease'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Each disease stage is further notated according to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>B symptoms</strong> – The presence ("B") or absence ("A") of systemic B symptoms is described below. (See <a class="local">'B symptoms'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bulky disease </strong>– The size of bulky disease should be reported, as described below. (See <a class="local">'Bulky disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extranodal involvement</strong> – The subscript "E" is used to describe extranodal extension in patients with limited stage cHL. "E" is not considered to be relevant in advanced-stage disease. (See <a class="local">'Extranodal involvement'</a> below.)</p><p></p><p class="headingAnchor" id="H3970064444"><span class="h2">Nodal regions</span><span class="headingEndMark"> — </span>Lymph node involvement is determined by physical examination and/or positron emission tomography/computed tomography (PET/CT). Diagnostic CT or magnetic resonance imaging (MRI) may be useful to further define the anatomy of certain PET-positive sites. Occasionally, biopsy of suspicious nodes is needed if imaging studies are indeterminate and treatment decisions would be affected by confirmation of involvement. Use of diagnostic CT or MRI for validation of PET findings is described above. (See <a class="local">'PET/CT'</a> above.)</p><p>Lymph nodes are divided into the following anatomic regions  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>); note that for staging purposes, the tonsils, Waldeyer's ring, and spleen are considered nodal tissue:</p><p class="bulletIndent1"><span class="glyph">●</span>Waldeyer's ring (tonsils, base of the tongue, nasopharynx)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ipsilateral cervical and supraclavicular</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occipital and pre-auricular</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infraclavicular</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Axillary and pectoral</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal – Mediastinal nodes include thymus, prevascular, aortopulmonary; paratracheal, pretracheal, subcarinal, and posterior mediastinal involvement; all nodal disease within the mediastinum is considered to be a single lymph node region. </p><p></p><p class="bulletIndent1">Internal mammary nodes are part of the lymphatic system of the chest wall and drain the diaphragm. Paravertebral nodes, although in the posterior mediastinum, also drain the chest wall and diaphragm. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hilar – Hilar nodes are considered separate from the mediastinum and should be considered to be "lateralized" (right hilar and left hilar nodes are separate regions) such that, when involved on both sides, constitute stage II disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Para-aortic</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spleen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iliac</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ipsilateral inguinal and femoral</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epitrochlear and brachial</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mesenteric nodes and popliteal nodes are also considered as separate nodal areas, although involvement of these two regions is almost never seen in early stage disease. </p><p></p><p class="headingAnchor" id="H379055322"><span class="h2">B symptoms</span><span class="headingEndMark"> — </span>Patients with the following are considered to have B symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained fever &gt;38°C during the previous month</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent drenching night sweats during the previous month</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss &gt;10 percent of body weight within six months of diagnosis</p><p></p><p>Patients who do not meet any of the above criteria are described with the letter A.</p><p>Fatigue, pruritus, alcohol-associated pain, and other symptoms are <strong>not</strong> considered B symptoms.</p><p class="headingAnchor" id="H2513097975"><span class="h2">Bulky disease</span><span class="headingEndMark"> — </span>Bulky disease should be described according to its size (eg, 15 cm mediastinal mass). It is no longer necessary in the Lugano staging system to designate bulky disease by the subscript "X." </p><p>There are several systems for defining bulky disease. We consider bulky disease to be [<a href="#rid1">1,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An abdominal node or nodal mass ≥10 cm in largest dimension as determined by CT, MRI, or ultrasound.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal mass on CT scan ≥10 cm or greater than one-third the internal transverse diameter of the thorax. We consider any of the following definitions of bulky disease to be acceptable for pretreatment evaluation of cHL:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mediastinal mass ratio (MMR)</strong> – MMR is the ratio of the maximum width of the mass and the maximum intrathoracic diameter; MMR &gt;0.33 is defined as bulky disease [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mediastinal mass ≥10 cm</strong> – A single node or notable mass ≥10 cm is considered bulky disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cotswalds definition</strong> – Bulky mediastinal mass is defined as more than one-third of the internal transverse diameter of the thorax at the T5-T6 interspace on a postero-anterior (PA) chest radiograph [<a href="#rid6">6</a>].</p><p></p><p>Other definitions of bulk disease (eg, ≥5 or ≥7 cm) have been suggested but are not used in routine clinical care of cHL [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H120890830"><span class="h2">Extranodal involvement</span><span class="headingEndMark"> — </span>The designation "E" refers to limited extranodal extension in patients with stage I or stage II disease.</p><p>The definition of limited extranodal disease is that which can be encompassed within an irradiation field that would be appropriate for nodal disease of the same anatomic extent. Limited extranodal disease is:</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of extralymphatic tissue on one side of the diaphragm by limited direct extension from an adjacent nodal site.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An apparently discrete single extranodal deposit consistent with extension from a regionally involved node. If a single extralymphatic site is the only site of disease, the staging should be classified as I<sub>E</sub>.</p><p></p><p>As an example, anterior extension of a mediastinal mass into the sternum or chest wall or extension to lung or pericardium should be recorded as extranodal extension (E). In contrast, diffuse or disseminated foci of one or more extralymphatic organs or tissues, with or without associated lymphatic involvement is designated as stage IV disease.</p><p>The presence of a single site of extranodal extension is considered to have a prognosis equivalent to that of nodal disease of the same anatomical extent. In contrast, disseminated extranodal disease (ie, stage IV) has an inferior prognosis. A retrospective study reported a striking difference in prognosis between patients with localized (ie, contiguous) extralymphatic organ involvement versus disseminated extralymphatic involvement [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Examples of staging</span><span class="headingEndMark"> — </span>The following are provided as examples of the application of the Lugano staging system [<a href="#rid1">1,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An asymptomatic patient with disease limited to nodes of the mediastinum with direct extension into the sternum would be staged as IA<sub>E</sub> disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An asymptomatic patient with bilateral cervical and right axillary lymph nodes with a small mediastinal mass would be staged as IIA disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A symptomatic patient with night sweats, weight loss of 15 kg, bilateral cervical node enlargement, a 15 cm mediastinal mass on chest CT, involvement of the right hilum, an abdominal CT showing para-aortic and pelvic adenopathy with no definite involvement of the liver, and no evidence of bone marrow involvement on PET would be staged as IIIB (15 cm mediastinal mass).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A symptomatic patient with disseminated extralymphatic involvement would be staged as IVB.</p><p></p><p class="headingAnchor" id="H1165815875"><span class="h1">TREATMENT STRATIFICATION</span></p><p class="headingAnchor" id="H2124961835"><span class="h2">Early versus advanced disease</span><span class="headingEndMark"> — </span>For treatment stratification, cHL is divided into:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early stage</strong> <strong>(stages I and II)</strong> – Early stage cHL is defined as stages I or II. (See <a class="local">'Staging notation'</a> above.)</p><p></p><p class="bulletIndent1">Patients with early stage disease are further stratified into favorable and unfavorable categories. Definitions of favorable and unfavorable disease  (<a class="graphic graphic_table graphicRef55327" href="/z/d/graphic/55327.html" rel="external">table 4</a>) are provided below. (See <a class="local">'Favorable early stage'</a> below and <a class="local">'Unfavorable early stage'</a> below.)</p><p></p><p class="bulletIndent1">Whether patients with stage II with bulky disease should be treatment as limited stage versus advanced disease is a source of controversy, as discussed below. (See <a class="local">'Advanced stage disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced stage</strong> <strong>(stages III and IV)</strong> – Patients with advanced cHL should be evaluated with the international prognostic score (IPS), as described below. (See <a class="local">'International Prognostic Score (IPS)'</a> below.)</p><p></p><p class="headingAnchor" id="H1310586768"><span class="h2">Early stage</span><span class="headingEndMark"> — </span>Stages I and II. (See <a class="local">'Staging notation'</a> above.)</p><p class="headingAnchor" id="H3322612050"><span class="h3">Unfavorable early stage</span><span class="headingEndMark"> — </span>The most common definitions of unfavorable stage I to II disease are those of the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin Study Group (GHSG). No prognostic model for early stage cHL has proven itself superior for risk stratification and either of these definitions is acceptable:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EORTC</strong> – The EORTC defines the unfavorable prognostic group as one or more of the following risk factors [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;50</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large mediastinal adenopathy (defined as mediastinal mass width measuring &gt;1/3 of the thoracic width at the T5-6 level)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Erythrocyte sedimentation rate (ESR) ≥50 mm/h and no B symptoms or (ESR ≥30 mm/h in those with B symptoms)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥4 sites of involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GHSG</strong> – The GHSG defines the unfavorable prognostic group as one or more of the following risk factors [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large mediastinal adenopathy (defined as mediastinal mass measuring &gt;1/3 of the maximum thoracic diameter)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ESR ≥50 mm/h and no B symptoms or (ESR ≥30 mm/h in those with B symptoms)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥3 sites of involvement</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extranodal involvement</p><p></p><p>A retrospective study applied the GHSG, EORTC, and National Comprehensive Cancer Network (NCCN) models  (<a class="graphic graphic_table graphicRef55327" href="/z/d/graphic/55327.html" rel="external">table 4</a>) to 1173 patients with early stage cHL [<a href="#rid13">13</a>]. The three models classified similar percentages of patients as having unfavorable prognosis early stage cHL (56, 55, and 57 percent, respectively). Each model had comparable high sensitivity (79 to 84 percent) but modest specificity (53 to 55 percent) for identifying patients with inferior progression-free survival (PFS) and overall survival (OS).</p><p>Management of early stage unfavorable prognosis cHL is described separately. (See  <a class="medical medical_review" href="/z/d/html/4690.html" rel="external">"Treatment of unfavorable prognosis early (stage I-II) classic Hodgkin lymphoma in adults"</a>.)</p><p class="headingAnchor" id="H4251987493"><span class="h3">Favorable early stage</span><span class="headingEndMark"> — </span>Favorable prognosis early stage<strong> </strong>cHL is defined by the <strong>absence</strong> of the criteria for unfavorable disease. (See <a class="local">'Unfavorable early stage'</a> above.)<strong> </strong></p><p>Management of early stage favorable prognosis cHL is described separately. (See  <a class="medical medical_review" href="/z/d/html/4754.html" rel="external">"Treatment of favorable prognosis early (stage I-II) classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H1021049258"><span class="h2">Advanced stage disease</span><span class="headingEndMark"> — </span>Advanced stage cHL includes patients with stages III to IV. Patients with advanced stage cHL should be evaluated with the IPS, as described below. (See <a class="local">'International Prognostic Score (IPS)'</a> below.)</p><p>Several cooperative groups include patients with stage II disease with one or more risk factors in their advanced-stage trials [<a href="#rid9">9,14,15</a>].</p><p>Management of advanced stage cHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4689.html" rel="external">"Initial treatment of advanced (stage III-IV) classic Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H2773508811"><span class="h1">PROGNOSTIC SCORING</span></p><p class="headingAnchor" id="H9398231"><span class="h2">International Prognostic Score (IPS)</span><span class="headingEndMark"> — </span>Patients with advanced stage cHL should be evaluated with the IPS. The IPS does not need to be applied to patients with early stage cHL; rather, treatment stratification of patients with stages I to II cHL is described above. (See <a class="local">'Early stage'</a> above.)</p><p>The IPS was developed from a retrospective review of clinical features and outcomes in &gt;5000 patients with cHL  (<a class="graphic graphic_table graphicRef76219" href="/z/d/graphic/76219.html" rel="external">table 5</a>) (<a class="calc calc_professional" href="/z/d/html/13486.html" rel="external">calculator 1</a>) [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin &lt;4 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin &lt;10.5 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;45 years</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV disease</p><p class="bulletIndent1"><span class="glyph">●</span>White blood cell count ≥15,000/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Absolute lymphocyte count &lt;600/microL and/or &lt;8 percent of the total white blood cell count</p><p></p><p>One point is given for each of the characteristics above (total score of 0 to 7). Following are rates of freedom from progression (FFP) and OS in an analysis of 740 patients with advanced stage cHL treated with <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a> (ABVD) from 1980 to 2010 [<a href="#rid17">17</a>]. At a median follow-up of 77 months, FFP and OS at five years correlated with IPS as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>No factors – FFP 88 percent, OS 98 percent (8 percent of patients)</p><p class="bulletIndent1"><span class="glyph">●</span>One factor – FFP 84 percent, OS 97 percent (26 percent of patients)</p><p class="bulletIndent1"><span class="glyph">●</span>Two factors – FFP 80 percent, OS 91 percent (26 percent of patients)</p><p class="bulletIndent1"><span class="glyph">●</span>Three factors – FFP 74 percent, OS 88 percent (21 percent of patients)</p><p class="bulletIndent1"><span class="glyph">●</span>Four factors – FFP 67 percent, OS 85 percent (12 percent of patients)</p><p class="bulletIndent1"><span class="glyph">●</span>Five or more factors – FFP 62 percent, OS 67 percent (7 percent of patients)</p><p></p><p class="headingAnchor" id="H1364166572"><span class="h2">Other prognostic factors</span><span class="headingEndMark"> — </span>Pathologic features have been evaluated as potential prognostic factors for cHL, but none is routinely applied in clinical practice.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor grade</strong> – Grading schemes have been proposed for cHL, but there is no clinical mandate to apply them in practice and they are not used for stratifying treatment. The British National Lymphoma Investigation (BNLI) and the GHSG include various cellular features (eg, composition of the inflammatory infiltrate, atypia of Hodgkin/Reed-Sternberg cells) to grade cHL [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory infiltrate</strong> – The numbers of infiltrating macrophages and eosinophils in the inflammatory infiltrate may have prognostic value in cHL. Several studies have reported that increased numbers of macrophages in the inflammatory infiltrate correlated with a higher risk of relapse [<a href="#rid20">20-23</a>]. </p><p></p><p class="bulletIndent1">Increased expression of proteins in the programmed cell death pathway by Hodgkin/Reed-Sternberg cells might also be related to overall clinical prognosis [<a href="#rid24">24,25</a>]. In one study, the presence of high numbers of active caspase-3 positive HRS cells was associated with higher rates of complete remission and OS [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV) </strong>– The presence of EBV is generally associated with inferior prognosis in cHL, compared to patients who are EBV-negative. Approximately one-third to one-half of cases are EBV-positive, based on immunostaining for latent membrane protein (LMP)-1 or EBV-encoded RNA (EBER) [<a href="#rid27">27,28</a>]. The highest percentage of EBV-positive cases are in children &lt;10 years and adults &gt;55 years [<a href="#rid27">27-29</a>]. In a study of 922 patients with cHL, EBV positivity was independently associated with increased HL-specific mortality and inferior survival in adults ≥45 years [<a href="#rid30">30</a>]. A prospective study also reported that patients with EBV-positive tumors had inferior survival [<a href="#rid31">31</a>]. A cooperative group study of adults with newly diagnosed cHL reported that plasma EBV viral genome copy number may have prognostic value in cHL [<a href="#rid32">32</a>]. </p><p></p><p class="headingAnchor" id="H3339555956"><span class="h1">OTHER PRETREATMENT MANAGEMENT</span></p><p class="headingAnchor" id="H2219303585"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>All patients with cHL should be counseled to stop smoking. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Patients should be offered psychosocial counseling similar to that described for the survivor of cHL. (See  <a class="medical medical_review" href="/z/d/html/14232.html" rel="external">"Approach to the adult survivor of classic Hodgkin lymphoma", section on 'Psychosocial issues'</a>.)</p><p class="headingAnchor" id="H2834709585"><span class="h2">Immunization</span><span class="headingEndMark"> — </span>Immunization for the adult with cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p class="headingAnchor" id="H3262774990"><span class="h2">Fertility preservation</span><span class="headingEndMark"> — </span>Individuals with childbearing potential should receive counseling about the potential effect of cHL and treatment on fertility and options for fertility preservation. Although ABVD (<a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>) chemotherapy is not associated with infertility, referral may be warranted in the event of refractory disease or relapse that requires other types of treatment.</p><p>It is useful to note that some males with cHL (especially those with B symptoms or other adverse features) may have impaired quantity or quality of sperm prior to treatment [<a href="#rid33">33</a>]. However, sperm quality before treatment is generally good enough for future fatherhood, and males should be encouraged to participate in sperm banking.</p><p>For females, cryopreservation of ovarian tissue/oocytes and other approaches are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.) </p><p class="headingAnchor" id="H2812277682"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Our approach to staging is consistent with those of the United States National Comprehensive Cancer Network, Lugano classification, and other international groups [<a href="#rid1">1,34</a>].</p><p>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/120313.html" rel="external">"Society guideline links: Management of Hodgkin lymphoma"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/683.html" rel="external">"Patient education: Hodgkin lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic Hodgkin lymphoma (cHL)</strong> – cHL includes the following histologic categories:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodular sclerosis cHL</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte-rich cHL</p><p class="bulletIndent2"><span class="glyph">•</span>Mixed cellularity cHL</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte-depleted cHL</p><p></p><p class="bulletIndent1">Nodular lymphocyte-predominant Hodgkin lymphoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Pretreatment evaluation includes (see <a class="local">'Pretreatment evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History, physical examination, and screening laboratory studies. (See <a class="local">'History and physical examination'</a> above and <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart and lung function</strong> – (See <a class="local">'Cardiac function'</a> above and <a class="local">'Pulmonary function tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Positron emission tomography (PET)/computed tomography (CT) </strong>– (See <a class="local">'PET/CT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – In selected cases, diagnostic CT, chest radiography, and/or other procedures may be used in staging cHL. (See <a class="local">'Diagnostic CT'</a> above and <a class="local">'Magnetic resonance imaging'</a> above and <a class="local">'Chest radiography'</a> above and <a class="local">'Other procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – Staging is based on the Lugano criteria  (<a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">table 3</a>), which describes the sites of involvement (stages I to IV), presence of B symptoms (fever, sweats, weight loss), bulky disease, and extranodal extension. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1">Description of nodal regions  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>) and criteria for B symptoms, bulky disease, and extranodal extension are provided above. (See <a class="local">'B symptoms'</a> above and <a class="local">'Bulky disease'</a> above and <a class="local">'Extranodal involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stratification</strong> – For the purpose of treatment, patients with cHL are stratified according to stage:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early stage (stages I or II)</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Unfavorable early stage</strong> – Based on European Organization for the Research and Treatment of Cancer (EORTC) or German Hodgkin Study Group (GHSG), as described above (see <a class="local">'Unfavorable early stage'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Favorable early stage</strong> – Absence of unfavorable criteria (see <a class="local">'Favorable early stage'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advanced stage</strong> <strong>(stages III and IV)</strong> – Patients with advanced stage cHL should be evaluated with the International Prognostic Score (IPS). (See <a class="local">'Advanced stage disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic scoring</strong> – IPS, which is applied only for patients with advanced stage cHL, includes patient age, sex, disease stage, and measurements of serum albumin, hemoglobin, white blood cell count, and absolute lymphocyte count  (<a class="graphic graphic_table graphicRef76219" href="/z/d/graphic/76219.html" rel="external">table 5</a>) (<a class="calc calc_professional" href="/z/d/html/13486.html" rel="external">calculator 1</a>). (See <a class="local">'International Prognostic Score (IPS)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other pretreatment management</strong> – Other pretreatment management includes immunization and counseling for smoking cessation and fertility preservation. (See <a class="local">'Other pretreatment management'</a> above.)</p><p></p><p class="headingAnchor" id="H2002466323"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges the late Peter M Mauch, MD for his previous contributions to this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104:1066.</a></li><li><a class="nounderline abstract_t">El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30:4508.</a></li><li><a class="nounderline abstract_t">Moulin-Romsee G, Hindié E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010; 37:1095.</a></li><li><a class="nounderline abstract_t">Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860.</a></li><li><a class="nounderline abstract_t">Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.</a></li><li><a class="nounderline abstract_t">Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048.</a></li><li><a class="nounderline abstract_t">Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978; 42:1039.</a></li><li><a class="nounderline abstract_t">Gallamini A, Tarella C, Viviani S, et al. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J Clin Oncol 2018; 36:454.</a></li><li><a class="nounderline abstract_t">Kumar A, Burger IA, Zhang Z, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica 2016; 101:1237.</a></li><li><a class="nounderline abstract_t">Musshoff K, Boutis L. Therapy results in Hodgkin's disease Freiburg i.Br., 1948-1966. Cancer 1968; 21:1100.</a></li><li><a class="nounderline abstract_t">Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.</a></li><li><a class="nounderline abstract_t">Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol 2013; 24:3070.</a></li><li><a class="nounderline abstract_t">Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013; 31:684.</a></li><li><a class="nounderline abstract_t">Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27:4548.</a></li><li><a class="nounderline abstract_t">Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.</a></li><li><a class="nounderline abstract_t">Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 2012; 30:3383.</a></li><li><a class="nounderline abstract_t">MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989; 64:1686.</a></li><li><a class="nounderline abstract_t">von Wasielewski R, Seth S, Franklin J, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000; 95:1207.</a></li><li><a class="nounderline abstract_t">Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012; 120:3280.</a></li><li><a class="nounderline abstract_t">Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood 2015; 125:1693.</a></li><li><a class="nounderline abstract_t">Touati M, Delage-Corre M, Monteil J, et al. CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma 2015; 56:332.</a></li><li><a class="nounderline abstract_t">Koh YW, Park CS, Yoon DH, et al. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One 2014; 9:e87066.</a></li><li><a class="nounderline abstract_t">García JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101:681.</a></li><li><a class="nounderline abstract_t">Montalbán C, García JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22:1664.</a></li><li><a class="nounderline abstract_t">Dukers DF, Meijer CJ, ten Berge RL, et al. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood 2002; 100:36.</a></li><li><a class="nounderline abstract_t">Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998; 12:1272.</a></li><li><a class="nounderline abstract_t">Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70:375.</a></li><li><a class="nounderline abstract_t">Enblad G, Sandvej K, Sundström C, et al. Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncol 1999; 38:425.</a></li><li><a class="nounderline abstract_t">Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23:7604.</a></li><li><a class="nounderline abstract_t">Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002; 119:432.</a></li><li><a class="nounderline abstract_t">Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 2013; 121:3547.</a></li><li><a class="nounderline abstract_t">van der Kaaij MA, Heutte N, van Echten-Arends J, et al. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica 2009; 94:1691.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/hodgkin_blocks.pdf (Accessed on February 21, 2019).</li></ol></div><div id="topicVersionRevision">Topic 4748 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047335" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150698" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204358" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5121694" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Report of the Committee on Hodgkin's Disease Staging Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809679" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113771" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/698907" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The significance of mediastinal involvement in early stage Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360414" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27390360" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4967490" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Therapy results in Hodgkin's disease Freiburg i.Br., 1948-1966.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818855" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24148816" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182987" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704068" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819449" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869887" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2790683" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666192" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948049" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575542" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766492" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24489836" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393683" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117989" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12070005" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9697883" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9033642" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10418708" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186595" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406082" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hodgkin's disease in the elderly: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23386127" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850901" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
